

Participant name:	
Hospital ID:	
CHI/Date of Birth:	

SOPHIST - Sotagliflozin in Patients with Heart failure Symptoms and Type 1 Diabetes

Sponsor University of Dundee-NHS Tayside
 Chief Investigator Dr Ify Mordi
 IRAS number 1007807

Principal Investigator	
Contact number	
Contact email	

Visit 3 – Baseline & Randomisation

Date of visit: Participant trial ID:

Please tick to indicate the following have been completed:

Confirmed participant's identity	<input type="checkbox"/>
Participant has verbally given their consent to continue in the trial	<input type="checkbox"/>
Concomitant medications have been reviewed	<input type="checkbox"/>
Adverse events have been reviewed	<input type="checkbox"/>
Education/review of glucose and ketone management undertaken including hypoglycaemic and DKA events, glucose/ketone readings, and insulin doses	<input type="checkbox"/>
Six-minute walk test	<input type="checkbox"/>
Urine pregnancy test, if women of childbearing potential	<input type="checkbox"/>
Urine albumin, creatinine and sodium	<input type="checkbox"/>
Full blood count, urea & electrolytes, liver function tests and glucose	<input type="checkbox"/>
Research blood and urine samples, according to participant consent	<input type="checkbox"/>
Participant was randomised as per protocol	<input type="checkbox"/>
Participant has been given trial medication	<input type="checkbox"/>

Physical characteristics and vital signs

Weight	<input type="text"/>	kg
Systolic/Diastolic BP	<input type="text"/>	mmHg
Pulse	<input type="text"/>	bpm

Insulin dose reduction (ONLY applicable for participants with HbA1c at screening lower than 58 mmol/mol or 7.5%)

Was insulin dose reduced by 10%? yes no

The following should be filed in the participant's medical notes:

- Eligibility criteria confirmation signed and dated by doctor on delegation log
- Changes to concomitant medications since last visit

Participant name:	
Hospital ID:	
CHI/Date of Birth:	

- Any adverse events since last visit
- Details of review of diabetes management including any changes to insulin or other diabetes medication
- Any hypoglycaemic and DKA events since last visit
- Any other notable findings and actions taken
- Copy of all laboratory test printouts signed and dated by doctor on delegation log
- Pregnancy test results, if applicable, signed and dated by doctor on delegation log
- If the participant was withdrawn from the trial at this visit, document reason

Any further information of note:

--

The visit has been carried out as per protocol.

Signature:	
Name:	
Job title:	
Date:	